相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
Karin M. Knudson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications
Warren J. Leonard et al.
IMMUNITY (2019)
An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck
Ashley Pinette et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
Caroline Jochems et al.
ONCOIMMUNOLOGY (2019)
Common gamma chain cytokines and CD8 T cells in cancer
Mitra Shourian et al.
SEMINARS IN IMMUNOLOGY (2019)
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression
Rika Fujii et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models
Bai Liu et al.
CYTOKINE (2018)
Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
Cristina Bergamaschi et al.
CYTOKINE (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
Stacy J. Kowalsky et al.
MOLECULAR THERAPY (2018)
Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes
Dionysios C. Watson et al.
PLOS PATHOGENS (2018)
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Meili Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Kim Margolin et al.
CLINICAL CANCER RESEARCH (2018)
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Jeffrey S. Miller et al.
CLINICAL CANCER RESEARCH (2018)
The potential and promise of IL-15 in immuno-oncogenic therapies
Tanya O. Robinson et al.
IMMUNOLOGY LETTERS (2017)
Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent
Yin Guo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
Maximillian Rosario et al.
CLINICAL CANCER RESEARCH (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
Bai Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists
Melanie Desbois et al.
JOURNAL OF IMMUNOLOGY (2016)
IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
Peter S. Kim et al.
ONCOTARGET (2016)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
Thomas A. Waldmann
CANCER IMMUNOLOGY RESEARCH (2015)
Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15•IL-15Rα Cytokine Compared to IL-15 Monomer
Elena Chertova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
Marie Vincent et al.
ONCOIMMUNOLOGY (2013)
Fc-fusion proteins: new developments and future perspectives
Daniel M. Czajkowsky et al.
EMBO MOLECULAR MEDICINE (2012)
IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
Kai-Ping Han et al.
CYTOKINE (2011)
High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer
Anne Bessard et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer
Meili Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Lnterleukin-15/interieukin-15Rα complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells
Mathieu Epardaud et al.
CANCER RESEARCH (2008)
Intracellular interaction of interleukin-15 with its receptor α during production leads to mutual stabilization and increased bioactivity
Cristina Bergamaschi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Combined IL-15/IL-15Rα immunotherapy maximizes IL-15 activity in vivo
Thomas A. Stoklasek et al.
JOURNAL OF IMMUNOLOGY (2006)
Converting IL-15 to a superagonist by binding to soluble IL-15Rα
Mark P. Rubinstein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ -: Hyperagonist IL-15•IL-15Rα fusion proteins
E Mortier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
分享论文
